Innate Pharma vs Molecular Partners
IPHA and MOLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IPHA and MOLN compare
Innate Pharma grew revenue faster over the last twelve months (−55.2% versus −100% for Molecular Partners).
Molecular Partners scores higher on the StockData Score (1 against 0 for Innate Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IPHA | MOLN |
|---|---|---|
| Size and price | ||
| Share price | $1.59 | $3.09 |
| Change, 1 year | −30.9% | −27.3% |
| Change, 5 years | −68.3% | −70.4% |
| Beta (5Y) | 0.95 | 0.90 |
| Employees | 181 | 34 |
| StockData Score | ||
| Total score | 0 | 1 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −55.2% (better) | −100% |
| Revenue growth, 5Y average | −33.6% | – |
| Profitability | ||
| Operating margin | −600% | – |
| FCF margin | −587% | – |
| Financial health | ||
| Interest coverage | −17.3× | −11.5× (better) |
| Current ratio | 0.60 | 7.27 (better) |
| Ownership | ||
| Held by institutions | 0.21% | 8.9% |
| Held by insiders | 16.2% | 0.00% |
Go deeper
- IPHA stock overview
- IPHA income statement
- IPHA valuation and score
- MOLN stock overview
- MOLN income statement
- MOLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.